Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA

• DOI: 10.1002/cncr.31314
• Publication Date: 2018-03-08T15:02:39Z
• Authors: Neeraj Agarwal; Sumanta K. Pal; Andrew W. Hahn; Roberto H. Nussen...; Gregory R. Pond; Sumati V. Gupta; Jue Wang; Mehmet A. Bilen; Gurudatta Naik; Pooja Ghatalia; Christopher J. Ho...; Dharmesh Gopalakr...; Pedro C. Barata; Alexandra Drakaki; Bishoy M. Faltas; Lesli A. Kiedrowski; Richard B. Lanman; Rebecca J. Nagy; Nicholas J. Vogel...; Kenneth M. Boucher; Ulka N. Vaishampayan; Guru Sonpavde; Petros Grivas
• Keywords: ARID1A; Cell-free fetal DNA

BACKGROUND Biomarker‐guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not available eligible. Technological advancements sequencing have made cell‐free circulating DNA (cfDNA) next‐generation (NGS) readily the clinic. The objective of current study was to determine whether genomic profile mUC detected by NGS cfDNA similar historical studies. A secondary frequency alterations (GAs) differed between lower tract (mLTUC) and upper (mUTUC). METHODS Patients from 13 academic medical centers United States who had a diagnosis 2014 2017 results were included. profiling performed using commercially platform (Guardant360) targeting 73 genes. RESULTS Of 369 with mUC, 294 diagnosed mLTUC 75 mUTUC. total 2130 GAs identified overall cohort: 1610 520, respectively, mUTUC cohorts. In cohort, frequently observed studies, including protein p53 ( TP53 ) P = 1.000 .115, respectively), AT‐rich interaction domain 1A ARID1A .058 .058, phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha PIK3CA .067, erb‐b2 receptor tyrosine kinase 2 ERBB2 .565 .074, fibroblast growth factor 3 FGFR3 .164 .014, respectively). No significant difference regard CONCLUSIONS Among no available, able identify biomarker‐driven compared tissue. Despite more aggressive course, cases demonstrated landscape that mLTUC. Cancer 2018;124:2115‐24 . © 2018 American Society